[Current status of the development of interceptive agents].
An account is given of present applications of interceptively acting substances. Pharmaceuticals used so far for postcoital conception (oestrogens, gestagens, and combinations of these) are suitable for single application, but their regular use is limited by side-effects. Various approaches are being taken to the development of effective interceptives for high-continuity application but with low side-effects. Antigestagens, LHRH-analogues, and immunological contraceptives seem to be among the most promising classes of substances for the above purpose. Yet, none of these substances has been developed as yet to the level of clinical applicability.
D000818:Animals; D003281:Contraceptives, Postcoital / Q000494:pharmacology*; D004338:Drug Combinations; D004965:Estrogen Antagonists; D004967:Estrogens / Q000494:pharmacology; D005260:Female; D006801:Humans; D010906:Pituitary Hormone-Releasing Hormones / Q000494:pharmacology; D010936:Plant Extracts / Q000494:pharmacology; D011372:Progestins / Q000037:antagonists & inhibitors / Q000494:pharmacology; D011453:Prostaglandins / Q000494:pharmacology; D011817:Rabbits; D051381:Rats; D012106:Research; D014612:Vaccines
D003281:Contraceptives, Postcoital; D004338:Drug Combinations; D004965:Estrogen Antagonists; D004967:Estrogens; D010906:Pituitary Hormone-Releasing Hormones; D010936:Plant Extracts; D011372:Progestins; D011453:Prostaglandins; D014612:Vaccines
Zum Stand der Entwicklung von Interzeptiva.